Affinity Investment Advisors LLC Sells 21,480 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Affinity Investment Advisors LLC decreased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 44.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 27,260 shares of the biopharmaceutical company’s stock after selling 21,480 shares during the period. Affinity Investment Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $458,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Aigen Investment Management LP raised its stake in shares of Catalyst Pharmaceuticals by 144.8% in the 4th quarter. Aigen Investment Management LP now owns 43,517 shares of the biopharmaceutical company’s stock valued at $732,000 after purchasing an additional 25,737 shares during the period. Franklin Resources Inc. raised its stake in shares of Catalyst Pharmaceuticals by 21.9% in the 4th quarter. Franklin Resources Inc. now owns 185,923 shares of the biopharmaceutical company’s stock valued at $3,125,000 after purchasing an additional 33,397 shares during the period. Assetmark Inc. raised its stake in shares of Catalyst Pharmaceuticals by 4.0% in the 4th quarter. Assetmark Inc. now owns 64,678 shares of the biopharmaceutical company’s stock valued at $1,087,000 after purchasing an additional 2,505 shares during the period. UBS Group AG raised its stake in shares of Catalyst Pharmaceuticals by 37.7% in the 4th quarter. UBS Group AG now owns 469,316 shares of the biopharmaceutical company’s stock valued at $7,889,000 after purchasing an additional 128,595 shares during the period. Finally, Navellier & Associates Inc. raised its stake in shares of Catalyst Pharmaceuticals by 12.9% in the 4th quarter. Navellier & Associates Inc. now owns 154,277 shares of the biopharmaceutical company’s stock valued at $2,593,000 after purchasing an additional 17,663 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Insider Transactions at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $15.68, for a total transaction of $392,000.00. Following the completion of the sale, the director now owns 348,874 shares in the company, valued at $5,470,344.32. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 11.00% of the company’s stock.

Analyst Upgrades and Downgrades

CPRX has been the topic of several recent research reports. StockNews.com downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. HC Wainwright lifted their target price on Catalyst Pharmaceuticals from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 target price on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th. Bank of America started coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 7th. They issued a “buy” rating and a $23.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $34.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, March 22nd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $26.71.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock traded down $0.26 during midday trading on Wednesday, reaching $16.27. 407,949 shares of the company’s stock were exchanged, compared to its average volume of 1,396,300. Catalyst Pharmaceuticals, Inc. has a 52 week low of $11.09 and a 52 week high of $17.50. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 30.44, a P/E/G ratio of 1.44 and a beta of 0.89. The stock’s 50-day simple moving average is $15.69 and its 200 day simple moving average is $14.99.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.04. Catalyst Pharmaceuticals had a return on equity of 25.08% and a net margin of 15.83%. The business had revenue of $110.57 million during the quarter, compared to analysts’ expectations of $105.78 million. Research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.78 earnings per share for the current year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.